THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Analysts puzzle over plan to sell a Vioxx-like drug

Furor over the Merck product spurred push to tighten FDA rules

By Diedtra Henderson
Globe Staff / March 30, 2007

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

Some analysts are scratching their heads at the move Merck & Co. is planning : The drug maker wants to sell a new painkiller that is just like Vioxx , the blockbuster drug it pulled from the market in 2004 because the treatment doubled heart risks. (Full article: 860 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass